HUP0302002A3 - Heterocyclic inhibitors of glycogen synthase kinase gsk-3, their use and pharmaceutical compositions containing them - Google Patents

Heterocyclic inhibitors of glycogen synthase kinase gsk-3, their use and pharmaceutical compositions containing them

Info

Publication number
HUP0302002A3
HUP0302002A3 HU0302002A HUP0302002A HUP0302002A3 HU P0302002 A3 HUP0302002 A3 HU P0302002A3 HU 0302002 A HU0302002 A HU 0302002A HU P0302002 A HUP0302002 A HU P0302002A HU P0302002 A3 HUP0302002 A3 HU P0302002A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
compositions containing
glycogen synthase
synthase kinase
heterocyclic inhibitors
Prior art date
Application number
HU0302002A
Other languages
English (en)
Original Assignee
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200001185A external-priority patent/ES2166328B1/es
Application filed by Consejo Superior Investigacion filed Critical Consejo Superior Investigacion
Publication of HUP0302002A2 publication Critical patent/HUP0302002A2/hu
Publication of HUP0302002A3 publication Critical patent/HUP0302002A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/395—Saturated compounds containing a keto group being part of a ring of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/597—Unsaturated compounds containing a keto groups being part of a ring of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0302002A 2000-05-11 2001-05-11 Heterocyclic inhibitors of glycogen synthase kinase gsk-3, their use and pharmaceutical compositions containing them HUP0302002A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200001185A ES2166328B1 (es) 2000-05-11 2000-05-11 Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
GB0030284A GB0030284D0 (en) 2000-05-11 2000-12-12 Enzyme inhibitors
PCT/GB2001/002100 WO2001085685A1 (en) 2000-05-11 2001-05-11 Heterocyclic inhibitors of glycogen synthase kinase gsk-3

Publications (2)

Publication Number Publication Date
HUP0302002A2 HUP0302002A2 (hu) 2003-09-29
HUP0302002A3 true HUP0302002A3 (en) 2007-02-28

Family

ID=26156184

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302002A HUP0302002A3 (en) 2000-05-11 2001-05-11 Heterocyclic inhibitors of glycogen synthase kinase gsk-3, their use and pharmaceutical compositions containing them

Country Status (19)

Country Link
US (3) US6872737B2 (hu)
EP (1) EP1286964B1 (hu)
KR (1) KR100812407B1 (hu)
CN (1) CN100358867C (hu)
AT (1) ATE366238T1 (hu)
AU (1) AU783615B2 (hu)
BR (1) BR0110734A (hu)
CA (1) CA2408747C (hu)
CY (1) CY1106826T1 (hu)
CZ (1) CZ296087B6 (hu)
DE (1) DE60129222T2 (hu)
DK (1) DK1286964T3 (hu)
ES (1) ES2288948T3 (hu)
HU (1) HUP0302002A3 (hu)
IL (1) IL152721A0 (hu)
MX (1) MXPA02011079A (hu)
PL (1) PL209780B1 (hu)
RU (1) RU2294931C2 (hu)
WO (1) WO2001085685A1 (hu)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152721A0 (en) * 2000-05-11 2003-06-24 Consejo Superior Investigacion Heterocyclic compounds and pharmaceutical compositions for inhibition of glycogen synthase kinase containing the same
WO2003018011A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
WO2003018554A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation 3-substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
EP1556088A2 (en) * 2002-10-29 2005-07-27 Engene, Inc. Compositions for cancer treatment
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
GB0327908D0 (en) * 2003-12-02 2004-01-07 Neuropharma Sa GSK-3 inhibitors isolated from marine organisms
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
EP1574499A1 (en) * 2004-03-08 2005-09-14 DKFZ Deutsches Krebsforschungszentrum Inhibitors of DNA methylation in tumor cells
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
WO2006034207A2 (en) * 2004-09-17 2006-03-30 Vanderbilt University Use of gsk3 inhibitors in combination with radiation therapies
WO2006045581A1 (en) * 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SE0500058D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
SE0500056D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4
CA2592771A1 (en) * 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators
JP2008526842A (ja) * 2005-01-10 2008-07-24 アストラゼネカ アクチボラグ 肝ｘ受容体モジュレーターとしてのイソチアゾール−３（２ｈ）−チオン１，１−ジオキシドのアニリン誘導体
PT1846406E (pt) 2005-02-09 2010-12-10 Arqule Inc Derivados de maleimida, composições farmacêuticas e métodos para o tratamento do cancro
ES2258406B1 (es) * 2005-02-10 2007-12-01 Neuropharma, S.A. Uso de compuestos heterociclicos como agentes neurogenicos.
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
CA2658263A1 (en) 2006-07-18 2008-01-24 University Of Rochester Thiadiazolidinone derivatives
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
CA2690799C (en) 2007-06-22 2015-06-16 Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CA2704282A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Quinazolinone compounds and methods of use thereof
US8513292B2 (en) 2007-06-22 2013-08-20 Arqule, Inc. Compositions and methods for the treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
DK2959900T3 (en) 2008-06-16 2017-06-26 Univ Tennessee Res Found CONNECTION TO TREATMENT OF CANCER
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN101519372B (zh) * 2009-04-01 2011-07-20 深圳市盛捷生物技术有限公司 用作GSK3抑制剂的苯并[e]异吲哚-1,3-二酮化合物及其制备
HUE027263T2 (hu) 2009-07-08 2016-10-28 Baltic Bio Ab 1,2,4-tiazolidin-3-on származékok és alkalmazásuk rák kezelésében
ITNA20090047A1 (it) * 2009-07-16 2011-01-17 Adele Bolognese Agenti antitumorali con attività inibitoria di proteine di prenilazione, processo di preparazione e impieghi in campo medico
WO2011079315A1 (en) 2009-12-23 2011-06-30 The Scripps Research Institute Tyrosine bioconjugation through aqueous ene-like reactions
EP3064204A1 (en) 2010-03-01 2016-09-07 GTx, Inc. Compounds for treatment of cancer
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
PL2647629T3 (pl) 2010-12-01 2015-12-31 Nissan Chemical Ind Ltd Związki pirazolowe o terapeutycznym działaniu na szpiczaka mnogiego
US11068954B2 (en) 2015-11-20 2021-07-20 Voicemonk Inc System for virtual agents to help customers and businesses
US8865750B2 (en) * 2011-04-28 2014-10-21 The Regents Of The University Of Michigan Small molecule inhibitors of RGS proteins
EP2527323A1 (en) 2011-05-24 2012-11-28 Noscira, S.A. Urea carbonyl disulfide derivatives and their therapeutic uses
WO2013020024A2 (en) * 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
LT2838888T (lt) 2012-02-24 2017-08-10 Asd Therapeutics Partners Llc Tiadiazolidindionai kaip gsk-3 inhibitoriai
CN103992312A (zh) * 2013-02-18 2014-08-20 江苏欧威医药有限公司 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用
SI2970890T1 (sl) 2013-03-14 2020-10-30 The Brigham And Women's Hospital, Inc. Sestavki in postopki za razmnoževanje in kultiviranje epitelijskih matičnih celic
EA026332B1 (ru) * 2013-03-14 2017-03-31 Общество с ограниченной ответственностью "Тиацен" Применение производных роданина для профилактики и/или лечения опухолевых заболеваний
US9795584B2 (en) 2013-07-30 2017-10-24 University Of South Florida Treating an atypical protein kinase C enzyme abnormality
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
EP3189134A1 (en) 2014-09-03 2017-07-12 The Brigham and Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US9540462B2 (en) 2014-12-05 2017-01-10 Massachusetts Institute Of Technology Catechol-rich polymers from N-substituted maleimides
SG11201707585UA (en) 2015-03-17 2017-10-30 Regeneron Pharma Amino acid acylation reagents and methods of using the same
US11021687B2 (en) 2016-01-08 2021-06-01 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
SG10201910821XA (en) 2016-12-30 2020-01-30 Frequency Therapeutics Inc 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
RU2761429C2 (ru) * 2018-06-13 2021-12-08 Общество с ограниченной ответственностью "Тиацен" Средство, обладающее противоопухолевым действием, для лечения онкологических заболеваний
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN110698380B (zh) * 2019-10-24 2021-01-15 华东理工大学 一种内酰胺衍生物及其制备方法与应用
KR20230147076A (ko) * 2021-02-11 2023-10-20 벤카 리서치, 인크. 부정맥유발성 심근병증 치료를 위한 조성물 및 방법
EP4340832A1 (en) 2021-05-21 2024-03-27 Amo Pharma Ltd. Method of treating rna repeat mediated diseases with rna repeat binding compound
EP4094760A1 (en) 2021-05-24 2022-11-30 Consejo Superior De Investigaciones Científicas Thiadiazolidinones for their use in the treatment of limb-girdle muscular dystrophy
CN115197167B (zh) * 2022-07-22 2023-07-28 中国药科大学 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2863803A (en) * 1957-05-13 1958-12-09 Stauffer Chemical Co Protecting materials against fungi by applying substituted dithiono and thiono-oxo-thiadiazolidines
US3301894A (en) 1964-11-16 1967-01-31 Olin Mathieson S-[nu'-(chlorocarbonyl)-amino] isothiocarbamyl chlorides and their preparation
DE1670701A1 (de) 1966-05-23 1970-11-12 Bayer Ag Verfahren zur Darstellung von Thiaimidazolidinen
US3900485A (en) 1967-02-10 1975-08-19 Velsicol Chemical Corp New substituted 1,2,4-thiadiazolidine-3,5-diones
US3534057A (en) 1968-05-28 1970-10-13 Velsicol Chemical Corp Halogenation process for the production of certain oxadiazolidines and thiadiazolidines
DE2109755A1 (de) 1971-03-02 1972-09-07 Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen Substituierte Thiadiazolidindione
US4183816A (en) * 1978-11-01 1980-01-15 Olin Corporation Use of 2,4-di(lower alkyl)-1,2,4-thiadiazolidin-3,5-diones as additives for functional fluids
JPS58216177A (ja) 1982-06-10 1983-12-15 Sumitomo Chem Co Ltd フエニルチアジアゾリジンジオン誘導体、その製造法および該化合物を有効成分として含有する除草剤
EP0817627B1 (en) * 1993-12-23 2005-03-09 Eli Lilly And Company Protein kinase c inhibitors
JP3714685B2 (ja) * 1994-05-18 2005-11-09 第一サントリーファーマ株式会社 ハイメニアルディシン及びその誘導体並びにそれらの合成中間体の製造法並びにその合成中間体
DE4420522A1 (de) * 1994-06-13 1995-12-14 Bayer Ag Bakterizide Thiadiazolidinone
ES2234300T3 (es) * 1998-10-08 2005-06-16 Smithkline Beecham Plc 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
GB9918180D0 (en) * 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions
IL152721A0 (en) * 2000-05-11 2003-06-24 Consejo Superior Investigacion Heterocyclic compounds and pharmaceutical compositions for inhibition of glycogen synthase kinase containing the same
GB0012056D0 (en) * 2000-05-18 2000-07-12 Consejo Superior Investigacion Model for neurodegenerative disease
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors

Also Published As

Publication number Publication date
CZ296087B6 (cs) 2006-01-11
RU2294931C2 (ru) 2007-03-10
MXPA02011079A (es) 2004-08-19
CN1568310A (zh) 2005-01-19
US20080033012A1 (en) 2008-02-07
KR100812407B1 (ko) 2008-03-11
DK1286964T3 (da) 2007-10-01
IL152721A0 (en) 2003-06-24
CZ20023692A3 (cs) 2003-06-18
AU5498101A (en) 2001-11-20
BR0110734A (pt) 2003-02-04
ATE366238T1 (de) 2007-07-15
US7781463B2 (en) 2010-08-24
CA2408747C (en) 2011-04-05
US7666885B2 (en) 2010-02-23
EP1286964B1 (en) 2007-07-04
WO2001085685A1 (en) 2001-11-15
KR20030025919A (ko) 2003-03-29
US6872737B2 (en) 2005-03-29
EP1286964A1 (en) 2003-03-05
US20030195238A1 (en) 2003-10-16
CA2408747A1 (en) 2001-11-15
US20050014803A1 (en) 2005-01-20
CN100358867C (zh) 2008-01-02
CY1106826T1 (el) 2012-05-23
PL209780B1 (pl) 2011-10-31
ES2288948T3 (es) 2008-02-01
AU783615B2 (en) 2005-11-17
DE60129222D1 (de) 2007-08-16
DE60129222T2 (de) 2008-03-06
HUP0302002A2 (hu) 2003-09-29
PL359671A1 (en) 2004-09-06

Similar Documents

Publication Publication Date Title
HUP0302002A3 (en) Heterocyclic inhibitors of glycogen synthase kinase gsk-3, their use and pharmaceutical compositions containing them
HUP0400908A3 (en) Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
HK1072936A1 (en) Inhibitors of glycogen synthase kinase 3
HUP0402330A3 (en) Amide derivatives as glycogen synthase kinase 3-beta inhibitors, process for producing them, pharmaceutical compositions containing them and use thereof
HUP0401819A3 (en) Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
MXPA03006420A (es) Diaminotiazoles.
HUP0402245A3 (en) Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
IL154016A0 (en) Pyrazole derivatives and their use as protein kinase inhibitors
ZA200207290B (en) Pharmaceutical compositions of glycogen phosphorylase inhibitors.
IL142113A0 (en) Use of glycogen phosphorylase inhibitors
HUP0303146A3 (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors and pharmaceutical compositions containing them
HUP0300340A3 (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases, pharmaceutical compositions containing them and their use
HUP0202708A3 (en) Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
HUP0500574A3 (en) Acridone inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use
EE05405B1 (et) Kinaasi inhibiitoritena toimivad bitskloprasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid
EP1601357A4 (en) HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
PL376789A1 (pl) Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
HUP0300318A3 (en) Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use
HUP0303698A2 (hu) Ciklin dependens kináz inhibitor N-[5-{[(5-alkil-2-oxazolil)-metil]-tio}-2-tiazolil]-karboxamid származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0300909A3 (en) 2-guanidino-4-arylchinazolines as nhe-3 inhibitors, pharmaceutical compositions containing them and their use
AU2003282976A1 (en) Inhibitors of glycogen synthase kinase 3
AU2003256410A8 (en) Combination therapy with p38 map kinase inhibitors and their pharmaceutical compositions
IL157740A0 (en) Heterocyclic derivatives and pharmaceutical compositions containing the same
IL161852A0 (en) Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: UNIVERSIDAD AUTONOMA DE MADRID, ES

Free format text: FORMER OWNER(S): CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, ES

Owner name: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICA, ES

Free format text: FORMER OWNER(S): CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, ES

FD9A Lapse of provisional protection due to non-payment of fees